Development of a single-shot subunit vaccine for HIV-1. 5. Programmable in vivo autoboost and long lasting neutralizing response

Journal of Pharmaceutical Sciences

Volumn 87, Issue 12, 1998, Pages 1489-1495

  Cleland, Jeffrey ^a   Lim, Amy ^a   Daugherty, Ann ^a   Barron, Lorena ^a   Desardin, Noelyn ^a   Duenas, Eileen ^a   Eastman, Donna ^a   Vennari, Joann ^a   Wrin, Terri ^a   Murthy, Krishna ^c   Powel, Michael ^d  

^a GENENTECH INC   (United States)

^b VaxGen Inc   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d Sofinnova   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROSPHERE; NEUTRALIZING ANTIBODY; POLYGLACTIN; QS 21; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; CONTROLLED STUDY; DRUG FORMULATION; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PULSATILE DRUG RELEASE; VACCINE PRODUCTION;

EID: 0031798160     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980263f     Document Type: Article

References (17)

1. Fast, P. E.; Sawyer L. A.; Wescott S. L. Clinical considerations in vaccine trials with special reference to candidate HIV-1 vaccines. In Vaccine Design: The Subunit Antigen Approach; Powell, M. F., Newman, M. J., Eds.; Plenum Publishing: New York, 1995; pp 97-124.
2. Hem, S. L.; White, J. L. Structure and properties of aluminumcontaining adjuvants. In Vaccine Design: The Subunit Antigen Approach; Powell, M. F., Newman, M. J., Eds.; Plenum Publishing: New York, 1995; pp 249-276.
3. Weissburg, R. P.; Berman, P. W.; Cleland, J. L.; Eastman, D.; Farina, F.; Frie, S.; Lim, A.; Mordenti, J.; Peterson, M. R.; Yim, K.; Powell, M. F. Characterization of the MN gpl20 HIV-1 vaccine: antigen binding to alum. Pharm. Res. 1995, 12, 1439-1452.
4. Cleland, J. L.; Kensil, C. R.; Lim, A.; Jacobsen, N. E.; Basa, L.; Spellman, M.; Wheeler, D. A.; Wu, J. Y.; Powell, M. F. The Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21. J. Pharm. Sei. 1996, 81, 22-28.
5. Cleland, J. L.; Powell, M. F.; Lim, A.; Ban-on, L.; Berman, P.; Eastman, D.; Nunberg, J.; Wrin, T.; Vennari, J. Development of a single shot subunit vaccine for HIV-1. AIDS Res. Hum. Retroviruses 1994, 10, S21-S25.
6. Cleland, J. L.; Lim, A.; Barren, L.; Duenas, E. T.; Powell, M. F. Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation and pulsatile release of MN rgpl20 from biodegradable microspheres. J. Controlled Release 1997, 45, 135-150.
7. Eldridge, J. H.; Staas, J. K; Meulbroek, J. A.; Tice, T. R.; Gilley, R. M. Biodegradable and biocompatible poly (D,Llactide-co-glycolide) microparticles as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991, 59, 2978-2984.
8. Cleland, J. L.; Barrön, L.; Daugherty, A.; Eastman, D.; Kensil, C.; Lim, A.; Weissburg, R. P.; Wrin, T.; Vennari, J.; Powell, M. P. Development of a Single-Shot Subunit Vaccine for HIV-1. 3. Effect of Adjuvant and Immunization Schedule on the Duration of the Humoral Immune Response to Recombinant MN gpl20. J. Pharm. Sei. 1996, 85, 1350-1357.
9. Cleland, J. L.; Barron, L.; Berman, P. W.; Daugherty, A.; Gregory, T.; Lim, A.; Vennari, J.; Wrin, T.; Powell, M. F. Development of a Single-Shot Subunit Vaccine for HFV-1. 2. Defining Optimal Autoboost Characteristics To Maximize the Humoral Immune Response. J. Pharm. Sei. 1996, 85, 13461349.
10. Powell, M. F.; Cleland, J. L.; Eastman, D.; Lim, A.; Murthy, K; Newman, M. J.; Nunberg, J. H.; Vennari, J. C.; Wrin, T.; Berman, P. Immunogenicity of the recombinant glycoprotein MN rgpl20/QS21 vaccine in primates. AIDS Res. Hum. Retroviruses 1994, 10, S105-S108.
11. Anderson, K. P.; Lucas, C.; Hanson, C. V.; Londe, H. F.; Izu, A.; Gregory, T.; Amman, A.; Berman, P. W.; Eichberg, J. W. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HFV1. J. Infect. Dis. 1989, 160, 960-967.
12. Berman, P. W.; Eastman, D. J.; Wilkes, D.; Nakamura, G. R.; Izu, A.; Schwartz, D.; Belshe, R.; Byrn, R. Comparison of the immune response to recombinant gpl20 in humans and chimpanzees. AIDS 1994, 8, 591-601.
13. Cleland, J. L.; Duenas, E. T.; Daugherty, A. L.; Marian, M.; Yang, J.; Wilson, M.; Celniker, A. C.; Shahzamani, A.; Quarmby, V.; Chu, H.; Mukku, V.; Mac, A.; Roussakis, M.; Gillette, N.; Boyd, B.; Yeung, D.; Brooks, D.; Maa, Y. F.; Hsu, C.; Jones, A. J. S. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J. Controlled Release 1997.
14. Miller, R. A.; Brady, J. M.; Outright, D. E. Degradation rates of oral resorbable implants (polylactates and polyglcolates): rate modification with changes in PLGA/PGA copolymer ratios. J. Biomed. Mater. Res. 1977, 11, 711-719.
15. O'Hagen, D. T.; Jeffery, H.; Davis, S. S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11, 965-969.
16. Haigwood, N. L.; Nara, P. L.; Brooks, E.; Van Nest, G. A.; Ott, G.; Higgins, K. W.; Dunlop, N.; Scandella, C. J.; Eichberg, J. W.; Steimer, K. S. Native but not denatured recombinant human immunodeficiency virus type 1 gpl20 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 1992, 66, 172-182.
17. Kreuter, J.; Berg, U.; Liehl, E.; Soliva, M.; Speiser, P. P. Influence of the hydrophobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1988, 6, 253-256.